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Abstract
Morin is a natural polyphenol,originally isolated from members of the Moraceae family, that can be
extracted  from  leaves,  fruits,  stems  and  branches  of  numerous  plants.  Several  evidence
demonstrated that Morin could have a beneficial effect on several human diseases. In fact, Morin
exerts antioxidant,  antidiabetic,  anti-inflammatory,  antitumoral,  antihypertensive,  antibacterial,
hypouricemic, and neuroprotective  effects, by modulating the activity of many enzymes. In some
cases, Morin  shows a systemic protective action, reducing negative side effects of several drugs,
without interfering with their functions. In addition,  in vitro and in vivo studies demonstrated that
Morin exhibits very low toxicity levels and its chronic administration is well tolerated. All these
findings  suggest  that Morin could be used,  either alone or in  combination with other drugs,  to
prevent many human pathologies.
Keywords:  Morin,  flavonoid,  polyphenol,  natural  drug;  anti-oxidant,  anti-diabetic;  anti-
inflammatory.
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Introduction
Plants, yeast and bacteria are the most important source of bioactive compounds for pharmaceutical
and medicine industry. In fact, several commercially available drugs, aimed to contrast bacterial in-
fections or to treat a wide range of diseases including diabetes, cancer and neurodegeneration, have
been directly derived from natural molecules or their semi-synthetic derivatives [1]. However, the
procedures leading to isolation and identification of pharmacologically active molecules from nat-
ural sources are often expensive and complicated,  due to their relative abundance and chemical
complexity.
Nevertheless, in many cases, this strategy has been successful, and allowed the identification of new
innovative  drugsand bioactive  compounds  Well-known  examples  are  acetylsalicylic  acid  and
metformin, derived from salicylic acid isolated from Salix alba, and galegine obtained from Galega
officinalis, respectively. In the last decades, many natural compounds have been characterized for
their pharmacological properties and have become drugs. It is not a coincidence that most of these
substances are contained in the extracts used for centuries by traditional medicine [2].
Morin,  3,5,7,2',4'-pentahydroxyflavone,  is  a  flavonol  isolated  as  a  yellow pigment  from plants
belonging to the Moraceae family. Morin is one of the principal constituents of many preparations
of botanical origin, and is recommended by traditional medicine to treat several human pathologies
[3]. Compelling evidence demonstrated that Morin is a bioactive compound, showing a broad range
of pharmacological activities and very low cytotoxicity. However, the action mechanism of Morin
remain  to  be  clarified.  Herein,  we  report  a  detailed  analysis  of  biological  properties  and
pharmacological activities of Morin.
Natural sources of Morin
Morin is present in several fruits and vegetables such as almond hulls [4], guava (Psidium guajava
L.) leaves [5], old fustic (Chlorophora tinctoria), mill (Prunus dulcis) [6], osage orange (Maclura
pomifera), Acridocarpus orientalis [7], onion, apple and in several beverages such as tea, red wine
[8], seaweeds [9], coffee and cereal grains. In addition, it represents one of the constituent of several
traditional herbal medicines [3].
Absorption and metabolism of Morin
Likewise other polyphenols, the free and glycosylated form of Morin can be detected in all its
natural  sources  [10;  11].  After  oral  uploading,  glycosylated,  methylated  or  sulfated  forms  of
polyphenols pass intact through stomach and reach the small intestine, where they are hydrolysed
by pancreatic and intestinal enzymes, and converted to the aglycone form [12; 13]. The hydrolysis
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step is essential to allow  their  intestinal absorption. In fact, most of glycosylated forms are not
uploaded from the enterocytes of small intestine, but are transported into the large intestine, where
they are metabolized from the resident bacteria.  Specific shuttle proteins enable the hydrophilic
morin aglycone to cross cellular membrane. Experiments carried out with human aortic endothelial
cells confirmed the involvement of an energy-dependent transport system in the delivery of Morin
from blood into the cells [14]. Likely, a similar mechanism contributes to transport Morin from the
intestinal lumen into enterocytes. Nevertheless, studies with human Caco-2 cells, demonstrated that
Morin possesses a very low intestinal permeability (Papp = 0.62 m/s) when compared with other
polyphenols [15]. In line with these findings, tests on Wistar rats have confirmed that the plasma
concentration  of  Morin  does  not  exceed 1%, also  after  oral  administration  of  high  doses  (200
mg/Kg)  [16].  The  poor  bioavailability  of  Morin  is  mainly  due  to  the  activity  of  Multidrug
Resistance-Associated  Protein-1,  a  carrier protein  widely  present  on  the  plasma-membrane  of
intestinal cells that is  responsible for the extrusion of Morin [15]. The inhibition of the Multidrug
Resistance-Associated Protein-1 by specific  drugs  significantly increases Morin upload,  thereby
confirming  the  role  of  this  transporter  in  regulating  intestinal  absorption  of  Morin  [17].  Once
absorbed, specific enzymes convert Morin into its glucuronidated, methylated and sulfated forms ,
which are then poured into the bloodstream [18].
A significant  increase  of  Morin  aglycone  in  the  blood,  can  be  detected  after  high  oral  dose
administration  (>100  mg/Kg)  of  Morin,  suggesting  that  activities  of  intestinal  glucuronyl
transferase/sulfotranferase enzymes are easily saturable [19].  Moreover, it has been demonstrated
that  hepatic  enzymes,  such  as  glucuronyl-transferase/sulfo-transferase  [19],  or  non-hepatic
cytochrome P450 and sulfotransferases, participate to Morin metabolism [20].
Physiological effects of Morin
Citotoxicity
Several studies demonstrated the low cytotoxicity of Morin on cellular cultures and animal models.
In  vitro,  Morin  showed  weak  cytotoxic  effects  (IC50=250  ±  40  µM)  on  human  promyelocytic
leukemia cells [21]. Moreover, in vivo studies revealed no toxic effects of Morin on F344 rats. After
13 weeks treatment with high Morin doses (from about 300 to 2400 mg/Kg b.w.) the rats didn’t
show any adverse effects, displaying only a modest alteration of liver functionality or a moderate
increase in liver or kidney weight. Based on these observations, authors calculated the no-observed-
adverse-effect level of Morin at about 300 mg/Kg of body weight/day [22].
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Antiperglycemic and antidiabetic activity
In an attempt to identify the herbal preparations with antidiabetic activity, some researchers have
analysed more than 160 traditional medicinal plant extracts. The methanolic extract of  Psidium
guajava L., which contains a high concentration of Morin, was one of the most active preparations
[23].  This extract  is  able  to  inhibit  the activity  of PTP1B, one of the most  important  enzymes
involved in  the negative  regulation of  insulin  receptor  signalling pathway [24].  In vivo studies
demonstrated that diabetic mice daily treated with Psidium guajava extracts, showed a significant
reduction of glycaemia, as well as a decrease in lipid liver deposits [25]. Similarly, the  Psidium
guajava  Linn extracts  showed  a  significant  antihyperglycemic  and  antioxidative  effect  in
streptozotocin-induced diabetic rats [26]. Moreover, lower blood glucose levels has been detected
in subjects affected by maturity-onset diabetes and in healthy volunteers after  administration of
Psidium  guajava extracts.  [27].  These  evidence  suggested  that  extracts  containing  high  Morin
concentration can complement orthodox anti-diabetic therapies. 
In vitro screening test, using in-house collection of 19 polyphenols, identified Morin as a potent
non-competitive  inhibitor  of  the  PTP1B  enzyme.  HepG2  cells  treated  with  25-50  µM  Morin
exhibited increased insulin receptor phosphorylation, resulting in increased glycogen synthesis and
in a decreased gluconeogenesis. In addition, it has been observed that Morin stimulates the insulin
activity, suggesting that it can act as insulin mimetic and insulin sensitizer [28]. More recently, other
experimental  evidence  confirmed that  Morin  is  able  to  improve glucose  metabolism control  in
animal models. Vanitha P.  et al. showed that Morin administration (50 mg/kg b.w.) contributes to
decrease  the  blood  glucose  levels  at  fasting  in  streptozotocin-induced  diabetic  rats  [29].  The
observed effects are comparable with those obtained following administration of glibenclamide, a
well-known antidiabetic drug. The effectiveness of Morin is, at least in part, linked to its ability to
protect  pancreatic  insulin-producing  cells  from death,  thereby  sustaining  insulin  release,  blood
glucose absorption, and glycogen synthesis in liver [29]. Interestingly, it  has been observed that
effectiveness  of  Morin in  the control  of  the postprandial  glycaemia in  diabetic  rats  is  strongly
enhanced when Morin is administered as zinc complex [30]. In fact, in diabetic rats, the chronic
treatment with low doses of the zinc-Morin complex (5 mg/kg b.w.) resulted in a glucose level
decrease  at  fasting,  in  an  improvement  in  insulin  sensitivity,,  in  a  reduction  of  the  level  of
glycosylated haemoglobin, circulating lipids and lipoproteins with respect to untreated diabetic rats.
No  significant  adverse  effects  or  alterations  in  both  carbohydrate  and  lipids  metabolism were
observed in  the control  rats  following the administration of the zinc-Morin complex [30].  It  is
important to consider that zinc ions are also potent inhibitors of PTP1B enzyme [31],  and that
intracellular zinc fluctuations contribute to the modulation of activity of several phosphotyrosine
protein phosphatases and to the regulation of specific signalling pathways [32]. Hence, Morin may
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contribute to enhance insulin receptor signalling by two different mechanisms: i)  direct inhibition
of PTP1B, ii) by increasing transport of zinc ions into the cells (Figure 1). 
Diabetes  induces  various  complications  including  neuropathy,  endothelial  dysfunction,  and
retinopathy. These effects are partially due to the covalent modification of proteins and lipids by
glucose.  These  glycosylated  adducts,  named  “advanced  glycation  end  products”are  thought  to
contribute  to  the  development  of  micro-  and  macrovascular  diseases.  Interestingly,  it  has  been
observed that Morin inhibits protein glycosylation in a concentration dependent manner, [33]. In
diabetic rats, one week treatment with Morin (15-30 mg/Kg b.w.)  significantly decreases the level
of inflammatory markers (TNF, IL1, IL-6) in brain,  , meanwhile increasing the circulating levels
of neurotrophic factors, thereby exerting a neuroprotective action. These results suggest that Morin,
besides to represent an effective anti-diabetic agent, could protect nervous cells from degeneration,
avoiding the onset of the  encephalopathy in subjects affected by diabetes [34].
Antioxidant activityReactive oxygen species (ROS) are implicated in the regulation of several cell
signalling pathways. When ROS production exceeds the ROS scavenging activity of antioxidant
enzymes (i.e. superoxide dismutase, catalase and glutathione peroxidase), proteins, carbohydrates,
lipids, and nucleic acids, can be damaged [35]. Polyphenols are natural antioxidants that can act as a
first line of cellular defence toward ROS [36]. Antioxidant activity of Morin is mainly due to the
presence of a double bond between C2-C3 atoms as well as to the presence of a hydroxyl group
activating the double bond at the C-3 position. Moreover, anti-lipid-peroxidation activity of Morin
seems to be strictly related with the presence of two hydroxyl groups on the 2' and 4' positions of
the B ring [37-39]. While the hydroxyl group in 4' position of B ring is thought to be responsible for
the antiradical activity of Morin, Myricetin, and Quercetin, the hydroxyl group in position 2' of B
ring, exclusively present in Morin, seems to be related to its more effective antiradical activity.  By
in silico studies, Morales J. et al. [40; 41]  demonstrated that the hydroxyl group in position 2' of B
ring forms a hydrogen bond with the oxygen atom in position 1 of C ring, inducing rotation of the B
ring,  which   acquires  a  planar  configuration  respect  to  ring  C.  This  configuration  favours  the
transmission of electronic effects from the B ring to the double bond of C ring, thereby making
Morin a good natural radical scavenger [42]. In vitro Morin inhibits the oxidation of LDL induced
by  2,2'-azo-bis-(2-amidinopropane)  dihydrochloride  and  contributes  to  prevent  oxidized  LDL
uptake  by  macrophages,  reducing  expression  of  CD36,  the  receptor  responsible  for  their
internalization. Furthermore, Morin can be useful to prevent negative effects of lipid peroxidation,
contributing  to  atherosclerosis  prevention  [43;  44]  and  protecting  cardiomyocytes,  endothelial
cells, and erythrocytes from the oxidative action of peroxyl radicals generated following treatment
with pro-oxidant agents such as 2,2'-azo-bis (2-amidinopropane) dihydrochloride, xanthine oxidase
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plus  hypoxanthine  system,  menadione,  3-morpholinosydnonimine-N-ethylcarbamide (SIN-1),  N-
nitrosodiethylamine.  Interestingly,  in  all  cases  Morin  resulted  more  effective  than  classical
antioxidant compounds such as Trolox (a vitamin E analogue), mannitol, and ascorbate [45-49].
Jonnalagadda J.V. et al. [50] demonstrated that Morin, due to its antioxidant and anti-inflammatory
activity, protects rats from Gentamicin-induced nephrotoxicity. In fact, Gentamicincytotoxic effects
are mainly mediated by ROS, which  trigger and sustainchronic inflammatory response that is the
cause of  tubular necrosis [51]. Administration of Gentamicin in combination with Morin (from 50
to 200 mg/Kg b.w./day) for fifteen consecutive days, leads to a decrease of the antibiotic-induced
nephrotoxicity,  reduction  of  cells  damage,  and  improvement  of  kidney  functionality.  In  vitro
experiments  showed  that  Morin  protects  lung  fibroblasts  from  DNA damage  and  from  lipid
peroxidation caused by exposition to H2O2 or γ-irradiation [52; 53]. Pre-treatment with Morin (100
mg/kg  b.w.)  in  mice  irradiated  with -irradiation  strongly  reduces  the  intestinal  mucosa
deterioration, inhibits inflammation and cells death, by preventing the intracellular reducing agents
depletion and the malondialdehyde production. These results suggested that Morin behaves as a
potent radioprotective agent [54]. Moreover, Kapoor R. et al showed that Morin decreases the ROS
levels  in  primary  rat  hepatocytes  exposed  to  high  glucose  concentration  (40  mM),  thereby
contributing to maintain mitochondrial integrity, to inhibit release of pro-apoptotic proteins, and to
prevent DNA damages [55].  In keeping with these findings,  in vivo  studies showed that Morin
treatment  (100  mg/Kg  b.w.)  protects  rat's  liver  exposed  to  cyclophosphamide  from  oxidative
damage [56]. Similar results  have also  been obtained  by Ray S.  et al  on rabbits treated with
cyclophosphamide/flutamide  Besides  to  protect  from the  oxidative  stress,  Morin  contributes  to
prevent  the  cholesterol  increase [57].  Morin  minimizes  the  side  toxic  effect  induced  by  some
chemotherapy agents such as doxorubicin and mitomycin C. In fact, Kok L.D. et al [58], showed
that Morin administration protects non-malignant cells from cytotoxic activity of drugs, without
interfering  with  their  effectiveness.  Morin  can also  inhibit  xanthine  oxidase,  one  of  the  most
important enzyme involved in the ROS production following ischemic-reperfusion events [59; 60].
In addition, it has been observed that Morin stimulates the expression of genes encoding proteins
involved in the antioxidant response (such as superoxide dismutase, catalase, heme oxygenase-1,
glutathione peroxidase and glutathione reductase) both in vitro and  in animal models,  preserving
the intracellular levels of glutathione, ascorbic acid and α-tocopherol [52; 61-63] (Figure 2).
Metal ions are essential for cells, being cofactors of several proteins and enzymes. Nevertheless,
when present in excess, they can contribute to elevate intracellular ROS levels through different
mechanisms,  such  as  the  Fenton  reaction.  Several  polyphenols  are  able  to  chelate  metals,
contributing to reduce their toxicity. Accordingly, it has been observed that  in vitro Morin forms
stable complexes with transition metal ions, such as iron, copper, chromium and cobalt, thereby
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inhibiting free metal-catalysed ROS production [64; 65]. In some cases, metal-Morin complexes are
more potent free radical scavengers than free Morin, mainly due to the acquisition of additional
superoxide dismutating centers [66].
Antinflammatory and antiallergic activity
Chronic  inflammation  contributes  to  the  development  of  pathologies  such  as  cancer,  diabetes,
cardiovascular and chronic bowel diseases, as well as of neurodegenerative disorders [67; 68]. At
the  molecular  level,  numerous  molecules  and  factors,  including  cytokines,  chemokines,  pro-
inflammatory  transcription  factors  and  enzymes,  and  matrix  metalloproteinases,  regulate
inflammation.  Many data  show that  Morin  is  able  to  inhibit  most  of  the  effectors  involved in
inflammation acting as a potent anti-inflammatotry agent by inhibiting activated macrophage cells
both in vitro [69; 70] and in vivo [71]. In vivo experiments demonstrated that Morin administration
(from 10 to 200 mg/kg b.w.) reduces colitis  triggered by treatment with trinitrobenzenesulfonic
acid,  preserving  intestinal  cells  from damages.  In  fact,  rats  treated  with  Morin  show a  lower
deterioration of bowel, a fewer granulocyte infiltration in the intestinal mucosa, and lower levels of
leukotriene B4 and malondialdehyde with respect to untreated rats [72]. More recently, Sunil K. et
al [73] demonstrated that Morin inhibits the activity of the transcription factor NF-kB, one of the
most important effector in the inflammatory response [74]. Morin inhibits the IkBα kinase pathway,
favouring the stabilization of IkBα, thus reducing the expression of inducible form of nitric oxide
synthase, as well as of the COX-2, IL-6, IL-8, and TNF genes. Similar results were obtained using
LPS-stimulated  RAW 264.7  cells  and macrophages  derived from mice  models  [75].  Moreover,
Morin is effective in reducing liver inflammation of rats  fed with a high fructose diet.  Excessive
fructose consumption causes activation of the SphK1/S1P-NF-kB signalling pathway, which,  in
turn,  triggers  liver  inflammation,  insulin  resistance,  and  the  increase  of  fat  depots  [76;  77].
Treatment with Morin causes a down-regulation of SphK1 activity and blocks the NF-kB nuclear
translocation,  inhibiting secretion of IL-1β, IL-6 and TNF-α by hepatocytes [78]. Other  in vivo
studies  demonstrated  that  pre-treatment  with  Morin,  reduces  NF-kB  activation,  the  expression
levels of TNF-α, IL-1, IL-6, and iNOS, and protects mice from the hepatic damage [79]. Taken
together, these data demonstrated that anti-inflammatory activity of Morin is, in part, attributable to
its ability to inhibit the NF-kB activity [80].
Few data  are   available  on   the  anti-inflammatory  activity  of  Morin  metabolites,  but  they  are
probably the main effectors of the observed phenomena. In keeping with this hypothesis, it has been
observed that sulfates/glucuronides metabolites of Morin strongly reduce the production of NO,
TNF-α,  and IL-12 in  macrophages  activated  with  LPS.  Interestingly,  these  metabolites  show a
potency 1000 fold higher than Morin. [81].
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Studies on mast cells suggested that Morin possesses also anti-allergic activity. For example, Morin
inhibits the release of IL-6, IL-8, and TNF-α from human umbilical cord blood-derived cultured
mast cells [82; 83]. Analyses of signalling pathways showed that Morin-induced inhibition of mast
cells degranulation is mediated by the inhibition of Syk kinase activation [84]. In fact, Morin is a
reversible inhibitor (IC50 value of 5.7 μM) of Fyn kinase, the main positive effector of Syk kinase in
mast  cells  following  IgE-mediated  activation  [85].  In  vivo  experiments  confirmed  that  Morin
suppresses IgE-mediated PCA in mice and inhibits degranulation and production of TNF-α and IL-4
in antigen-stimulated mast cells. Thus, reversible inhibition of Fyn kinase is the main mechanism
through which Morin exerts its anti-allergic activity [86].
 
 Antitumoral activity
Cancer is  the second leading cause of death in  the western countries  [87].  Carcinogenesis  is  a
multistep process, encompassing several stages consistent with initiation, which elicits oncogenes
activation  or  DNA  damages,  promotion,  in  which  anomalous  cells  proliferate  generating
preneoplastic  foci,  and progression,  the final stage in which preneoplastic  cells  shift  toward an
uncontrolled and invasive phenotype [88]. It has been suggested that numerous natural compounds,
including Morin, exert an anticancer preventive activity, reducing DNA damages and modulating
signalling pathways involved in proliferation and differentiation [89].
Chemopreventive activity
Morin inhibits carcinogenic activity and tumor-promoting activity of several chemical compounds.
For  instance,  treatment  with  Morin  (50  mg/kg  for  three  days)  protects  rats  treated  with  7,12-
dimethylbenz(a)-anthracene from oxidative stress, decreases the expression of tumor markers and
inhibits  tumor  growth  [90].  Moreover,  it  has  been  observed  that  Morin  blocks  liver  cells
transformation induced by 12-O-tetradecanoylphorbol-13-acetate [91].
These  evidence suggest  that  Morin could  act  as  an  anticancer  agent  better  than other  classical
cytotoxic drugs.
Inhibition of proliferation and induction of apoptosis
Morin inhibits  proliferation of cancer cells  by interfering with cell  cycle.  Brown J.  et al  [92]
demonstrated  that  Morin  induces  the  G2/M  phase cell  cycle  arrest in human  oral  squamous
carcinoma cells, without inducing apoptosis.  Other evidence demonstrated that Morin is able to
induce apoptosis in LNCaP prostate cancer cells and in Human Leukemia HL-60 cells. In HL-60
cells Morin promotes the activation of caspase-3 and Bax, stimulates expression of caspase-3 and -
9, triggers cytochrome c release from mitochondria and decreases expression of antiapoptotic Bcl-2
9
expression.  These data  suggest  that apoptosis  induced by Morin might  involve a  mitochondria-
dependent pathway and   caspase-3 [8; 93]. Recently, studies conducted on multiple myeloma cells
demonstrated  that  Morin  increases  apoptosis  of  cancer  cells  through  the  SHP1-mediated
inactivation  of  STAT3  (signal  transducers  and  activator  of  transcription  3)  signalling  pathway.
Finally, it has been demonstrated that Morin increases apoptosis of the cancer cells by 30%, without
affecting viability of normal cells [94].
Modulation of signalling pathways
In animals treated with pro-carcinogenic agent 7,12-dimethylbenz(a)-anthracene, Morin treatment
inhibits tumor growth and decreases the expression of breast cancer specific tumor markers, thereby
confirming its anti-carcinogenic activity [90]. In addition, Morin could prevent the growth and the
dissemination of metastatic cancer cells by inhibiting the activity of NF-kB transcription factor. In
fact, a low Morin dose (50 μM) is sufficient to revert mesenchymal phenotype of highly metastatic
MDA-MB-231  breast  cancer  cells,  reducing  expression  of  N-cadherin,  metalloproteinase-9
secretion, and inhibiting activation of Akt pathway [95].
Inhibition of pro-carcinogenic effects of metal compounds
Morin binds metal ions such as iron, copper, chromium, vanadium and cobalt, thus inhibiting ROS
production  through  the  Fenton  or  Haber–Weiss  reactions.  In  addition,  Morin  prevents  metal-
catalyzed free radicals generation, thereby protecting biologically active molecules from oxidative
stress. It is interesting to note that metal-Morin complexes are more effective than Morin alone in
removing free radicals [96-98].
Effects on phase I enzymes and on P-glycoprotein
The  therapeutic  efficacy  of  many  anticancer  drugs depends  in  part  on  expression  of  drug-
metabolising enzymes such as those belonging to cytochrome P450 family.  These enzymes are
mainly expressed  in liver cells, but are also found  in the cells of esophageal squamous mucosa,
duodenum, and jejunum [99].  Many studies carried out on animal models,   showed that Morin
inhibits expression of Cytochrome P450-2C9 isoenzyme in liver [100] and of Cytochrome P450-
3A4 [101] in intestinal mucosa. Cytochrome P450 enzymes play a key role in the metabolism of
sterols, prostaglandins, drugs, or xenobiotic compounds. In some cases, these enzymes contribute to
conversion of  xenobiotic  compounds in highly reactive metabolites able  to react  with proteins,
lipids or nucleic acids, thereby initiating the carcinogenesis process. Polyphenols and Morin can: i)
increase the plasma lifetime of chemotherapy drugs, thus improving their effectiveness; ii) inhibit
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cytochrome  P450-mediated  carcinogen  activation,  reducing  intracellular  amount  of  pro-
carcinogenic compounds [102].
Failure of chemotherapy is  often due to high activity of P-glycoprotein,  a an efflux membrane
transporter  over-expressed  in  several  type  of  tumors.  The  P-glycoprotein  contributes  to  the
extrusion of many molecules, including anticancer drugs, immunosuppressants and antibiotics, thus
preventing  them  from  reaching  their  physiological  targets.  For  this  reasons  P-glycoprotein  is
considered  a  key  player  in  the  induction  of  chemoresistance  toward  a  large  number  of
chemotherapy  drugs  such  as  taxanes,  etoposide,  and  vinca-alkaloids  [103].  Several  studies
demonstrated that Morin inhibits P-glycoprotein, thereby acting as a bio-enhancer that increases the
bioavailability and bioefficacy of drugs [104-106]. This hypothesis is confirmed by independent
studies  showing  that  Morin  increases  the  bioavailability  of  etoposide  [107],  tamoxifen  [108],
vinblastine [109], nicardipine [110], methotrexate [111], paclitaxel [112], daunomycin [113] and
talinolol [114] in normal rats, as well as of etoposide in mammary tumor-bearing rats [115]. These
findings suggest that Morin administration could increase the dose of drug absorbed by cells, thus
increasing treatment efficacy [116].
Anti-hypertensive activity
Genetic factors, obesity and diabetes have a relevant role in the development of hypertension, which
is one of the most important risk factors for cardiovascular diseases in the world [117]. Endothelial
dysfunction, inflammation, and excessive ROS production contribute to the development of this
pathological  condition,  suggesting  that  antioxidant  agents  could  be  used  as  adjuvants  to  the
treatment of hypertension [118; 119]. Herrera M.D. et al., reported that Morin contributes to relax
vessels contracted by noradrenaline, KCl, and  phorbol ester derivatives, and to enhance the effects
of classical anti-hypertensive drugs, such as isoprenaline and sodium nitroprusside [120]. Morin
administration (50 mg/kg for six consecutive weeks) improves the conditions of albino Wistar rats
treated with deoxycorticosterone acetate-salt, a potent hypertension-inducing factor. In particular, it
has been observed that Morin induces a considerable decrease of the systolic and diastolic blood
pressure,  and  a  decrease  of   hepatic  and  renal  functional  markers  with  respect  to  untreated
hypertensive rats. Similar results have been confirmed in a recent study, showing that renal and
cardiac damages induced by deoxycorticosterone acetate are reduced in animals pre-treated with
Morin [121; 122]. Beneficial effects of Morin have been described also in hypertensive rats feeded
with  a  diet  rich  in  fructose.  In  this  animals,  Morin  pre-treatment  causes  a  reduction  of  blood
pressure, of serum insulin, of triglyceride levels, and a downregulation of endothelin-1 expression, a
vasoactive  peptide  that  contributes  to  the  development  of  hypertension  [123].  In  addition,  in
diabetic rats Morin promotes the production of the vasorelaxant nitric oxide, and the inhibition of
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thromboxane A2, which acts as a vasoconstrictor. Taken together, these findings confirm the anti-
hypertensive role of Morin [124].
Antibacterial activity
Antimicrobial properties of many plant extracts have long been known [125; 126]. Kang S.S. et al
reported  that  Morin  inhibits  both  sortase  A and  B,  two  enzymes  expressed  in  Staphylococcus
aureus. In Gram-positive bacteria, Sortase A plays a critical function, modulating the adhesion of
bacteria  to the host tissue. Inhibition of sortase A by Morin prevents the establishment of infections,
without  affecting  microbial  viability  [127].  DNA helicase  is  another  enzyme  essential  for  cell
growth of bacteria, virus, and eukaryotic cells being involved in DNA metabolism .  In vitro tests
showed that Morin can inhibit ATPase activity of DNA helicase RepA, with an IC50 value of 45 M.
These results suggested that Morin could be useful to contrast growth of both  Gram-positive and
Gram-negative bacterial species [128]. Looking for natural antibacterial compounds, Arima H. and
Danno G. found that Morin-3-O--L-lyxopyranoside and Morin-3-O--L-arabopyranoside isolated
from leaves of guava (Psidium guajava L.) behave as antibacterial agents, showing a minimum
inhibitory  concentration  of  300  and  150  g/ml  for  Bacillus  cereus and  Salmonella  enteritidis,
respectively [11]. Further studies demonstrated that Morin inhibits growth of  E.coli and  S.aureus
[129]. More recently, it has been highlighted that Morin-3-O-arabinoside and Morin-3-O-lyxoside
extracted from P. guajava laves show antibacterial activity against several strains of spoilage and
foodborne  pathogenic  bacteria,  including  B.  stearothermophilus,  B.  thermosphacta,  E.  coli ,  L.
monocytogenes,  P. fluorescens,  S. enterica,  S. aureus, and  V. cholerae  (Figure 3). Taken together,
these findings suggest that Morin acts as food preservatives and can be useful to improve the shelf-
life and the safety of foods, thereby protecting humans from foodborne diseases.
Anti-uricemic activity
Uric acid is the final metabolite of purine catabolic pathwayand is  one  of  the  main antioxidant
agents of blood. The excess of uric acid is eliminated via the urine. When its synthesis is increased,
or its excretion is impaired, it rushes causing pain, chronic inflammatory, and kidney failure [130].
Recent studies demonstrated that Morin can be useful to reduce serum levels of uric acid in patients
suffering  of  hyperuricemia   .  It  has  been  observed  that  Morin  acts  through  two  different
mechanisms:  i)  by  inhibiting  liver  xanthine  oxidase  (Ki=7.9  μM),  thus  reducing conversion  of
xanthine into uric acid; ii) by inhibiting human urate anion transporter-1, the main responsible for
the urate reabsorption,present on the brush-border membrane of renal proximal tubule [131]. In vivo
studies   showed  that  in  hyperuricemic  animal  models,  the  treatment  with  Morin  leads  to  a
significant  reduction  of  the  plasma uric  acid  levels,  without  impairing  total  serum antioxidant
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capacity  or  causing  others  undesirable  side  effects  [132;  22].  Morin  administration  (50  and
100mg/kg  b.w.  for  3  days)  may  also  contribute  to  restore normal  levels  of uric  acid in  a
hyperuricemic mice model [133]. Moreover, Morin behaves as a competitive inhibitor of human
urate transporter in vitro with a Ki of about 6 μM, resulting more potent, but much less toxic, than
some  classical  urate-lowering  agents  (including  probenecid  and  sulfinpyrazone)  [134;  135].
Interestingly, Shi Y.W. et al reported that administration of ethanol extract of Ramulus Mori, which
contains mulberroside A, oxyresveratrol, 4-hydroxycinnamic acid, resveratrol, 7- hydroxycumarin
and Morin, contributes to regulate renal organic ion transporters, thereby reducing the levels of uric
acid and protecting the kidney function [136]. Taken together, these data suggest that Morin could
be considered an excellent alternative drug to the treatment of hyperuricemic patients.
Neuroprotective and anti-amyloidogenic activity
Neuronal cells are highly sensitive to environmental conditions, and  may suffer severe damages
when  exposed  to  oxidative  stress  conditions.  Chronic  ROS  production  triggers  and  feeds
inflammatory  processes,  thereby  inducing  apoptosis  of  nervous  cells  [137-138].  Compelling
evidence demonstrated that Morin exerts a relevant neuroprotective effect on cells and on animal
models,  and it  may be used as a new therapeutic agent for the treatment  of neurodegenerative
diseases. Morin exerts its activity through different mechanisms:
i) It  attenuates  ROS  formation  in  differentiated  PC12  cells  treated  with  1-methyl-4-
phenylpyridinium ion,  inhibits  caspase-3 activation and apoptosis.  In addition,  in animal
models,  Morin  treatment  relieves  symptoms of  Parkinson's  disease,  and  prevents
dopaminergic neuronal death and the striatal dopamine depletion in mice treated with 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine  [139].  Ibarretxe  G.  et  al [48]  showed  that
nanomolar concentrations of Morin protect oligodendrocytes and cortical neurons from ROS
accumulation mediated by AMPA receptors overstimulation.
ii) It  inhibits  glycogen  synthase  kinase  3,  a  pivotal  enzyme  involved  in  the  onset  of  the
Alzheimer disease. It has been demonstrated that dysfunction of glycogen synthase kinase 3
induces  alterations  in  the  choline  metabolism,  impairs  axonal  transport,  microtubule
dynamics  and  neurogenesis,  triggers  apoptosis,  blocks  the  differentiation  of  newborn
neurons, induces morphological alteration in neuronal cells and impairs their connectivity
[140]. Inhibition of glycogen synthase kinase 3 contributes to improve condition of patients
suffering  of  Alzheimer  disease.  Low  Morin  concentrations  (1-10  μM)  in  vitro  inhibits
glycogen synthase kinase 3 activity, thereby reducing Aβ-induced tau hyperphosphorylation,
without affecting cell viability. Comparable results were obtained with animal models of
Alzheimer disease. In these animals, Morin treatment (10 mg/kg b.w. for 7 days) results in a
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reduction of total levels of tau hyperphosphorylation, confirming the hypothesis that Morin
may have a potential role as therapeutic agent for treatment of tauopathies [141].
iii)  It inhibits NF-kB activity, thereby behaving as an anti-inflammatory agent.
iv)  It  inhibits  assembling  and/or  acts  as  disintegrating  agent  of  amyloid  fibers,  the  well
organized proteinaceous structures appearing in the late stages of degenerative pathologies
such  as  Alzheimer,  Parkinson’s  disease  or  type-2  diabetes.  [142].  Similar  results  were
obtained with peptide β-amyloid.  In vitro, Morin inhibits β-amyloid peptide fibrillogenesis
with IC50 value of about 25 µM and protects HT22 murine neuroblastoma cells from the
oxidative stress triggered by amyloid fibrils, confirming that this flavonoid, differently from
many other natural molecules, has a double action mechanism [143]. Nevertheless, the exact
mechanism by which Morin exerts its inhibitory activity on fibrillogenesis has not been yet
completely elucidated [144].  In silico analyses carried out using atomistic explicit-solvent
molecular dynamics simulations,  showed that  Morin binds to the ends of the β-amyloid
growing fibrils,  blocking the protein polymerization process [145].  Morin modifies both
tertiary  and  quaternary  structure  of  newborn  protofibrils,  thereby  inhibiting  their
cytotoxicity and their conversion in long mature amyloid fibrils [146].
v) It  inhibits  acetylcholinesterase  activity,  preventing  the  loss  of  acetylcholine,  a  typical
pathological event that characterizes patients affected by Alzheimer’s disease  [147]. 
vi) It  inhibits  β-Secretase  1,  the  enzyme  involved  in  the  abnormal  production  of  the
amyloidogenic peptide Aβ42.  In silico docking analysis revealed that Morin targets active
site  of   β-Secretase  1,  interacting  with  the  catalytic  residue  Asp228.  Morin  is  a  good
inhibitor of β-Secretase 1 and shows an IC50 value of about 20 µM [148].
vii)  It inhibits the membrane destructuring ability of wild type, and of  -synuclein mutants,
proteins implicated in the pathophysiology of both familial and sporadic Parkinson's disease.
Caruana M. et al showed that Morin and others polyphenols, such as baicalein and apigenin,
protect membrane against perturbations induced by aggregates obtained from wild-type and
some α-synuclein mutants.
Taken  together,  all  these  data  suggest  that  Morin  can  be  considered  an  interesting  starting
compound for the development of new generation drugs useful to the treatment of Parkinson's and
Alzheimer's disease [149].
Inhibitory activity of Morin on enzyme activity and protein function
Morin acts as inhibitor of key regulatory enzymes involved in the control of many intracellular
signalling pathways, showing IC50 or Ki values near to µM range (Table I). Morin binds into  the
active  site,  acting  as  competitive  inhibitor  of  the  cytochrome  P450-2C9,  of  monocarboxylate
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transporter-1, of multidrug resistance proteins 1 and 2, and of the fatty acid synthase. Nevertheless,
in other cases, the docking site of Morin remain to be identified. It has been reported that Morin
behaves as a non competitive inhibitor of DNA helicase RepA and PTP1B, or as a mixed type
inhibitor of urate-anion transporter. Finally, it has been suggested that  some polyphenols, including
Morin, could bind to specific sites on the enzymes surface, modulating theiractivity. For example,
X-ray analysis of the ATP synthase-Morin complex has actually identified a "polyphenol binding
pocket" [150]. Iglesias  et al [151] demonstrated that Morin is able to act as a potent inhibitor of
phospholipase A2 from Crotalus durissus cascavella venom, showing an IC50 value of about 5 M.
Morin interacts with the hydrophobic catalytic pocket of the enzyme, thereby inducing a strong
change  in  the  secondary  structure.  Nevertheless,  interaction  with  Morin  does  not  suppress
inflammatory and neurotoxic effects of phospholipase A2. Interestingly, independent works showed
that Quercetin,  a molecule structurally similar to Morin,  has a similar behaviour and is able to
inhibit  both  F1-ATPase  from bovine  heart  mitochondria  [152]  and  phospholipase  A2  from  C.
durissus terrificus venom [153]. Finally, Morin is able to interact with  human serum albumin with a
dissociation  constant  value  of  about  9  M.  The  bind  of  Morin  to  albumin  causes  significant
alteration of protein secondary structure content, suggesting that Morin could acts as a modulator of
albumin physiological functions [154].
Taken together, these evidence confirm that several enzymes and proteins possess binding sites for
polyphenols, thereby reinforcing the hypothesis that these natural compounds can participate to the
regulation of several human physiological functions.
Other activities of Morin
In  vitro studies  on  rat  chondrocytes,  have  demonstrated  that  Morin  is  able  to  inhibit
metalloproteinases  release  induced  by  IL-1β  stimulation,  thereby  preventing  breakdown  of  the
cartilage  matrix.  In  vivo investigation  on  a  rat  model  of  anterior  cruciate  ligament  transection
(ACLT)-induced osteoarthritis, demonstrated that Morin administration (50 mg/kg/d for four weeks)
inhibits  cartilage  degradation.  These  results  suggest  that  Morin  could  be  used  as  a  possible
therapeutic agent for the treatment of osteoarthritis [155].
Morin  has  been  reported  to  possess  protective  effect  on  hepatic  fibrosis  induced  by
dimethylnitrosamine in rats. Oral administration of Morin leads to reduction of hepatic expression
of collagen type I, TGF-β1, and α-SMA, some of most important hepatic fibrosis-related factors. In
addition, in dimethylnitrosamine treated rats, Morin administration normalizes the level of serum
alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin. These results suggest
that Morin may be useful also to prevent the development of hepatic fibrosis and cirrhosis [156].
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Finally,  flavonoids  such as Morin show inhibitory activity  against  a  variety of virus,  including
herpes simplex virus (HSV), respiratory syncytial virus, poliovirus and Sindbis virus.
Conclusions
Despite  the  improvement  of  knowledge  and  technologies,  the  war  against  pathologies  such  as
diabetes, cardiovascular diseases, cancer and neurodegenerative diseases is far from over. This is
due to a deficit of knowledge about the actual molecular mechanism contributing to the onset and
development of diseases and to the lack of innovative drugs. Many lines of evidence indicate that
development of new drugs is a key objective for the future.
To date, natural extracts or medicinal foods, recommended by traditional medicines to prevent or
treat several human pathologies, are the major font of innovative bioactive molecules.
In  the  last  years,  the  concept  of  dietary chemoprevention  is  gaining increasing  attention and
numerous natural compounds have recently been suggested as potential therapeutic agents. In this
context, Morin is a very interesting molecule with healing properties. One of the peculiarity of
Morin is its strong antioxidant and antiradical activity. Differently to other polyphenols, that can
generate ROS by undergoing auto-oxidation reactions [157], Morin retains its antioxidant character
also at  high concentration.  Morin is not toxic for animals for doses up to 300 mg/Kg of body
weight/day [158], and it is highly effective in protecting cells from oxidant insults generated by
oxidants, xenobiotics, excess of metals or radiations.  ROS can modulate the function of several
transcription  factors,  influencing  the  expression  of  genes  involved  in  the  synthesis  of  pro-
inflammatory cytokines, and can regulate cell survival and proliferation. This evidence can explain
why  Morin  may  act  also  as  a  potent  anti-inflammatory  and  antitumoral  agent.  Since  chronic
oxidative stress contributes to onset of diabetes, kidney failure, hypertension and neurodegenerative
diseases, we can suppose that Morin could exert a preventive activity toward such pathologies.
Thus,  the  ROS scavenger  activity  of  Morin  can  alone  justify  many of  the  observed beneficial
pharmacological activities.
Nevertheless, the direct interaction of Morin with protein targets or enzymes, strongly contributes to
the modulation of signalling pathways involved in the regulation of cells physiology or metabolism.
The high number of protein targets identified, suggest that Morin can simultaneously modulates  the
activity  of  different  signalling  pathway,  thereby  influencing  several  cellular  functions.  Finally,
Morin is  able  to inhibit  some cellular  membrane efflux transporters,  as  well  as some enzymes
belonging to cytochrome P450 family. The use of Morin to increase absorption and effectiveness of
drugs has been proposed and beneficial effects have been demonstrated.
In summary, to date a systemic analysis of Morin effects on human patients is still lacking. The few
tests performed on human patients confirm the data obtained with animal models [27] and, despite
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they are still insufficient to elect Morin as a true natural drug, they are an excellent starting point for
further investigations.
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AMPA  receptors,  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic  acid  receptor;  Trolox,  6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic  acid;  DNA,  Deoxyribonucleic  acid  IL8,
interleukin 8; RAW 264.7, macrophage cell line from Mus musculus, mouse; Sphk1, sphingosine
kinase 1; iNOS, Inducible nitric oxide synthase; Syk, Spleen tyrosine kinase; IgE, immunoglobuline
E;  PCA,  passive  cutaneous  anaphylaxis;  Fyn,  Src  family  tyrosine  kinase;  LNCaP,  androgen-
sensitive  human  prostate  adenocarcinoma  cells;  Akt/PKB,  protein  kinase B;  KCl,  Potassium
Cloride; ATPase, adenosine 5'-triphosphatase; PC12, pheochromocytoma of the rat adrenal medulla
cell  line;  Aβ42,  amyloid  beta 1-42;  Ki,  inhibition  constant;  RepA,  replicase  A;  TGF-β1,
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Table I: Inhibitory effect of morin on potential physiological substrates
Enzyme or protein IC50 
(μM)
Ki 
(μM)
Reference
Fyn kinase 5.7 [86]
Trypsin 27 [159]
Topoisomerase I 139 [160]
Topoisomerase II 135 [160]
Fatty acid synthase 2.3 [161]
Xantine oxidase 7.9 [132]
ATP synthase (E.coli) 70 [150]
Esterase 1.8 [162]
Beta-site APP Cleaving Enzyme-1, β-secretase 21.7 [148]
ATP synthase (rat) 60 [163]
Monocarboxylate transporter 1 6.4 [164]
Glycogen synthase kinase β 1-10 [141]
Aldose reductase ~ 1 [165]
Peroxisome proliferator-activated receptor-α 8.6 [166]
Peroxisome proliferator-activated receptor-β 16 [166]
Peroxisome proliferator-activated receptor-γ 43 [166]
PTP1B 5.9 [28]
TC-PTP 19 [28]
YopH 5 [28]
IF1 3.6 [28]
IF2 66 [28]
LTP1 99 [28]
Acetylcholinesterase 210 [147]
Sortase A 37.4 [127]
Sortase B 8.5 [127]
Cytochrome P4502C9 1.8 [101]
URAT1 17 [134]
Glutathione S-transferase P1-1 > 50 [167]
Glutathione Reductase 118.7 [168]
HIV-1 Proteinase 24 [169]
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Multidrug resistance proteins 1 49 [170]
Multidrug resistance proteins 2 > 50 [170]
Cytochrome P4502C9 (CYP1A2) 9.5 [100]
DNA helicase RepA 45 18.1 [128]
Human serum albumin 9 [154]
Phospholipases A2 ~ 5 [171]
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Figure Legends
Fig. 1. Molecular mechanism of insulin sensitizing action of Morin. Morin, in the free form or
complexed with Zn2+ ions,  passes through the plasma membrane. Morin and Zn2+ ions  interact
with enzymes involved in the negative regulation of insulin receptor, such as PTP1B and/or other
PTPs .
 
Fig. 2. Antioxidant, anti-inflammatory and antitumoral activity of Morin. Morin contributes to
neutralize  the  negative  effects  of  ROS.  Besides  to  inhibit  ROS  production,  Morin  stimulates
expression of several antioxidant enzymes (*), decreasing the intracellular ROS levels and NF-kB
transcriptional  activity. Morin  contributes  to  also  inhibit  P-glycoproteins  activity  enhancing the
effectiveness  of  chemoterapy  drugs.  As  a  consequence,  Morin  sensitizes  cancer  cells  against
apoptosis and inhibits cell migration and invasion. Finally, through inhibition of Cytochrome P450
family enzymes Morin, inhibits activation of pro-carcinogenic molecules.
Fig. 3. Antibacterial and neuroprotective effects of Morin.
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